Received: from WA1PEPF000099D3.eurprd04.prod.outlook.com
 (2603:10a6:e10:30:cafe::55) by OS6P279CA0004.outlook.office365.com
 (2603:10a6:e10:30::16) with Microsoft SMTP Server (version=TLS1_3,
 cipher=TLS_AES_256_GCM_SHA384) id 15.21.615.9 via Frontend Transport; Wed, 11
 Nov 2026 14:21:29 +0000
Received: from OS6P279CA0004.NORP279.PROD.OUTLOOK.COM (2603:10a6:e10:30::16)
 by AM7PR02MB6259.eurprd02.prod.outlook.com (2603:10a6:20b:1bd::11) with
 Microsoft SMTP Server (version=TLS1_2,
 cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.615.8; Wed, 11 Nov
 2026 14:21:30 +0000
Received: from mail3.rit.ee (213.184.59.150) by
 WA1PEPF000099D3.mail.protection.outlook.com (10.167.242.27) with Microsoft
 SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.615.4
 via Frontend Transport; Wed, 11 Nov 2026 14:21:29 +0000
Received: from [192.168.16.122] ([81.20.145.82] 82-145-20-81.sta.estpak.ee)
 (Authenticated sender: zmail-316038[teet.torgo@rhl.ee])
 by MTA-244-115.TLL07.ZONEAS.EU (ZoneMTA Forwarder) with ESMTPSA id 1a1cafc1d0c00017b6.001
 for <info@justdigi.ee>
 (version=TLSv1.2 cipher=ECDHE-RSA-AES256-GCM-SHA384);
 Wed, 11 Nov 2026 14:21:22 +0000
Received: from AM7PR02MB6259.eurprd02.prod.outlook.com (2603:10a6:20b:1bd::11)
 by AS8PR02MB7159.eurprd02.prod.outlook.com with HTTPS; Wed, 11 Nov 2026
 14:21:32 +0000
From: "Teet Torgo" <teet.torgo@rhl.ee>
To: "Justiits- ja Digiministeerium" <info@justdigi.ee>
Subject: =?utf-8?Q?Majandustegevuse_seadustiku_=C3=BCldo?=
	=?utf-8?Q?sa_seaduse_ja_ravimiseaduse_muut?=
	=?utf-8?Q?mise_seaduse_eeln=C3=B5ust?=
Date: Wed, 11 Nov 2026 16:21:21 +0200
Keywords: liivia
Message-ID: <2C5BF02B-5840-4B4D-BE74-2241EEE6C0E0@rhl.ee>
MIME-Version: 1.0
Content-Type: multipart/alternative;
	boundary="----=_NextPart_000_0050_01DD728A.B1B3B220"
X-Mailer: Microsoft Outlook 16.0
Thread-Index: AQI9kLEJ25am/JUkLM3Wa6dHEwmF7Q==
Authentication-Results: mx.microsoft.com 1; spf=softfail (sender IP is
 213.184.59.150) smtp.mailfrom=rhl.ee; dkim=pass (signature was verified)
 header.d=rhl.ee;dmarc=bestguesspass action=none
 header.from=rhl.ee;compauth=pass reason=109
X-CSE-ConnectionGUID: 3NA7R8wBQU6kxECgo+3ixw==
X-CSE-MsgGUID: Lj3OkgIiRSaKOEm8u9V7Uw==
X-ThreatScanner-Verdict: Negative
X-IPAS-Result: =?us-ascii?q?A0EPAwDmePRqe3P06lVXA4QWgQSBC4EUB1GEWJMglxeHY?=
 =?us-ascii?q?A8BAQEBAQEBAQgBAVEEAQEDAQOEfiGOASAGAUsBAgQDAgMBAQEBAQEBAQEBA?=
 =?us-ascii?q?QEKAQEBBAEBAQIBAQIEAwEBAQECEAEBQg47hk8NjBM7ghYsgTQaAwEBOBIGR?=
 =?us-ascii?q?AJNEYMVAYIkUJ57nB6BMoEBggwBAQaCatlLgWsJh0GCbgErgTUBAg6DeIVDg?=
 =?us-ascii?q?QNSRIEVJwsQiAwmNYJgOoIwgiZ6EoE+gRqNbYclgUQiAyYzLAFVExcLBwWBa?=
 =?us-ascii?q?AOBBjI8Mh2BIz4XL1gbBgWBHIEegRKBB12BKyheIYEIgXYCglGCAAIBSUEOB?=
 =?us-ascii?q?0VTCSVDEkckIggSCQETGiwKgRo1PAkmPxUMZwsaBWEIAg0MdDkQMB4kLwUaJ?=
 =?us-ascii?q?j4bCn5tPTcVGQSTP2LNTjQHhCOBYAgMgwGdBy+XapMIhiONCIVdqRkCBAIEB?=
 =?us-ascii?q?QIZNoFKgX4zGoEdAYI8UAMZD44uFhyEMM1QdzwBAgcCBwELAQEDCQEBgjiPZ?=
 =?us-ascii?q?IFMAQE?=
X-Talos-CUID: 9a23:+jjUn2z1XyN0rOZd809bBgVPPOl6SC3C5k7tfUyoJE1mT/7OSE+PrfY=
X-Talos-MUID: =?us-ascii?q?9a23=3Ahd7odwxR6m+O+KLIt1/RxBWxu5aaqICsU2cOnrQ?=
 =?us-ascii?q?HgfKNFgtdPmeA3Qrof5Byfw=3D=3D?=
X-IronPort-Anti-Spam-Filtered: true
X-IronPort-AV: E=Sophos;i="6.27,207,1787000400"; 
   d="scan'208,217";a="53242486"
X-DisclaimerOO: 1
X-MS-Exchange-Organization-ExpirationStartTime: 11 Nov 2026 14:21:29.5970
 (UTC)
X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit
X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000
X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit
X-MS-Exchange-Organization-Network-Message-Id: 186919e1-39ba-4ad0-1388-08df3fff1414
X-EOPAttributedMessage: 0
X-EOPTenantAttributedMessage: 8fe098d2-428d-4bd4-9803-7195fe96f0e2:0
X-MS-Exchange-Organization-MessageDirectionality: Incoming
X-MS-PublicTrafficType: Email
X-MS-TrafficTypeDiagnostic: WA1PEPF000099D3:EE_|AM7PR02MB6259:EE_|AS8PR02MB7159:EE_
X-MS-Exchange-Organization-AuthSource: WA1PEPF000099D3.eurprd04.prod.outlook.com
X-MS-Exchange-Organization-AuthAs: Anonymous
X-MS-Office365-Filtering-Correlation-Id: 186919e1-39ba-4ad0-1388-08df3fff1414
X-MS-Exchange-AtpMessageProperties: SA|SL
X-MS-Exchange-Organization-SCL: -1
X-Microsoft-Antispam: BCL:0;ARA:13230040|82310400026|260918215300599003|260918224100599003|260925021311599003|260925022911599003|260925021911599003|5063699009|11063799006|56012099006|55112099003|16102099003|19002099009|6133799003|261009220027099003|261009223327099003|261009221727099003|261009223027099003|261026140227099003|10067099003|261009221227099003|261102123227099003|261021121427099003|261022105027099003|261022075727099003|261026121527099003|261028144727099003|18003699003|8096899003|43540500003;
X-Forefront-Antispam-Report: CIP:213.184.59.150;CTRY:EE;LANG:et;SCL:-1;SRV:;IPV:NLI;SFV:NSPM;H:mail3.rit.ee;PTR:mail3.rit.ee;CAT:NONE;SFS:(13230040)(82310400026)(260918215300599003)(260918224100599003)(260925021311599003)(260925022911599003)(260925021911599003)(5063699009)(11063799006)(56012099006)(55112099003)(16102099003)(19002099009)(6133799003)(261009220027099003)(261009223327099003)(261009221727099003)(261009223027099003)(261026140227099003)(10067099003)(261009221227099003)(261102123227099003)(261021121427099003)(261022105027099003)(261022075727099003)(261026121527099003)(261028144727099003)(18003699003)(8096899003)(43540500003);DIR:INB;
X-MS-Exchange-CrossTenant-OriginalArrivalTime: 11 Nov 2026 14:21:29.3865
 (UTC)
X-MS-Exchange-CrossTenant-Network-Message-Id: 186919e1-39ba-4ad0-1388-08df3fff1414
X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2
X-MS-Exchange-CrossTenant-AuthSource: WA1PEPF000099D3.eurprd04.prod.outlook.com
X-MS-Exchange-CrossTenant-AuthAs: Anonymous
X-MS-Exchange-CrossTenant-FromEntityHeader: Internet
X-MS-Exchange-Transport-CrossTenantHeadersStamped: AM7PR02MB6259
X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.4077832
X-MS-Exchange-Processed-By-BccFoldering: 15.21.0615.005
X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(4710232)(4717077)(4999285)(920097)(930201)(20251009284)(140003);
X-Microsoft-Antispam-Message-Info: =?us-ascii?Q?pb4XSt/UbWa7dZ+sf/igbA2VsCvezYEPLBJQWb3Z2t97cpq1IW551o6mfdyr?=
 =?us-ascii?Q?IDevIJyXT1DNHM7BnCdVByribpvzrrX8uLkPQGbmpHefc2Cj8HqBlgmQUGv5?=
 =?us-ascii?Q?1mASaLb0OHJr07EDARgfqwsu1+NL5XVmuHVaFn7FF0fFWKY0fdBeWavNz7yO?=
 =?us-ascii?Q?oRsCXBQFf0E79x33455ZbpgcvCeEozrifMjJwGfTMYphSTc89Y3pDXH6139U?=
 =?us-ascii?Q?lNvSuZ5LBqXIrfwgBunaMsWmUS6eHd8P/jcbpkXHR0nwMj2SDC+ZpuTcB5Af?=
 =?us-ascii?Q?JDAD5rGhWcJIITk2HcinMRGh7hOYnZjtBjy8pfqPTuSgQyH/oRC2dWYG0YBL?=
 =?us-ascii?Q?HvS5dj7qZEcVKoM4aKRou5TaJyfJHQbIZ51QGRhVpvd8uLlm2L3RmV3cPl7f?=
 =?us-ascii?Q?aazSl4omaeB2oWWWn3LtSMhGTsgCk6n1pSFJgu71uxI23xVrqaFosAaiOAGM?=
 =?us-ascii?Q?bJ9iUcCnoKnEGrsz04yZCdnONOq+cpD5dL7PSHoR4w+aCqBT4SwB1a1OJtpQ?=
 =?us-ascii?Q?q35niUy+9DCU8D/KxvbelC5oVF1NYImi+7sll7eGquqAOwomB03aBmqltFBT?=
 =?us-ascii?Q?ZpvwnvCqfqvCN11IzoIFqmGxdSYnIrDbAO28xSvR4PpIm5shwV/Gy5lq7Ixz?=
 =?us-ascii?Q?EdJiZwM3SVPBr+gA8UtNTAGQXnSyg4lEyA/bPVM7mzRxRX3wYQkrX1V8cCIn?=
 =?us-ascii?Q?w0/gW1dTHUZO20yb3hyjF/xzbLsRj5+XHyGWQT5OKjDAIlmm3ZF
	vK8Uf38Jg?=
 =?us-ascii?Q?0U9JwWorhsSbIODeaOnecrsNJ/FCFSBj2CnFRV3gLTkiOcukIexniYEyGiaL?=
 =?us-ascii?Q?iBbm18iU/9838cyX6K9/emxq9cV9a9Dsy/q2TVDqnLEKtm7I/2a3fCDgXRZ6?=
 =?us-ascii?Q?clsoItpNEJ1xsvyyMN9qZxUgUtCEayH53cCtL102zW9MdoX93CHAkYIXZBjl?=
 =?us-ascii?Q?OYwTNB7WQNGUzPwtCftuCApBAsK6UMuXnWXQM8ZbppREmIFeSdNJNsc9lFu4?=
 =?us-ascii?Q?+mAIuWU5VDV/MpTXTC2ov6QkdTMX3xW0Gsdd1KHIUqb20MwzzfjyK4XTRhYd?=
 =?us-ascii?Q?Lk8cY0MEvHRP70DQLxD9Vj6eM3nnE32hFM4hBx1Sim+ddbhy1u93C7gQffv9?=
 =?us-ascii?Q?7L5uSTxF3FLC64gx7DkYZIeaQ3Y5ABwrkv8HzpbKVCpEuDz+e9PyRpBjtKdT?=
 =?us-ascii?Q?L5FmirMNRfRCK4nQcmy6G7CBLNNrTAplvCP2vSy+vsuTRAiShEWHLLDrcZWL?=
 =?us-ascii?Q?KinkUqwc3wlnvae0atpELmiVaLbl6mXFZoXNTRf1r5st2qsquwGFgdHzmlD3?=
 =?us-ascii?Q?SvE3xAP9ekTU2E/9hrYLojFLqdwn/BpIHVJy8rOMaBsp9qGYvGtZUxMgWYaR?=
 =?us-ascii?Q?Gd/UNFfeAYxNjA3XiZCzlVTJM5/WJFgYqG9b/+JSwoXegDMf1G3FFamMNa3N?=
 =?us-ascii?Q?z0fGfyp65XU3gewtqtzQF1v4ZUxHrINdb4Bcb/h1jrsFS0LhC2d8W9LLB3hk?=
 =?us-ascii?Q?UXP11ALk0vnFwZodZ4gdGFpc9OIioP4CL9e+H
	we4y5OagQth2ndClq4PDl1/?=
 =?us-ascii?Q?zuuvitEZAiuKwlv0RrKffHkYqyUgnqiGRcVQ4E20rooMVJxaL/PtP91EmbBL?=
 =?us-ascii?Q?gKfnCgdhxokP1dSOeISr89ZxeR/3yA4UN7NfrJAfDzJUFT+QVzotarMA1mVx?=
 =?us-ascii?Q?dEW2aNuB+NOrL+wItXJ0eNQ8CCeQF80ENfQ+I7hgaunzREFh7nxJlzCFgegi?=
 =?us-ascii?Q?Zbjrv9Id1IZeDZDbntxG6b/NsNjd8QUNFWpeuEA8bHiar0kOXUyMJ8OQmvbn?=
 =?us-ascii?Q?O59qwS6j/7kHRfPLpRRV7lmlzhKDPzD0OBREozObeBlOBYOMaHMSiKdnAvae?=
 =?us-ascii?Q?A66ZAy0yI2gHYEgpxWWf2JRn8gbsDpHQpg6rdMk8UuiLDB0/UK8WvnHUAAcO?=
 =?us-ascii?Q?N9IO0hz81rAzpFi/myUU33TAcq+7VfWaP4yXwEeAlFrrHN/e04kRKYop8c9O?=
 =?us-ascii?Q?DC0ZiG9vvzNjyhITAGgPydHJ1a/zE0rylgMFEYNGhwBugjpAvOnfVRo4OtPZ?=
 =?us-ascii?Q?CpcuRvSGrFvXrwJjp0eEvCHKnWYpifWMc5eoXBdPXSxVhnmi8ihO4fGGGuYz?=
 =?us-ascii?Q?8ddbpDEWHSmxrJYdMaSWffibcX85E9gOopQGhWJXz8yKOdrjQs2/aKKwmfPM?=
 =?us-ascii?Q?aS6Ch64YRe04BB7mqafm4H5B6TdWhoFv2JoXi2dXkDKgFfRFkTgauaudRrco?=
 =?us-ascii?Q?xpQHC82aWKiZo71AQS9WJn6PCPu5UTmCGU1BsL6bShC9MhivysSHjmT75hX6?=
 =?us-ascii?Q?RzCvflI8eWkcfQoJd8g1uee
	gdyO09N/ujqmL8yXYTnAfAku6+xl8RRnoGIT3?=
 =?us-ascii?Q?skrbe0jSGcjyQm+Uaa4U7eh7h+MdOo9vrZu7n3DSj8s0URxCNiP9eOxYTi00?=
 =?us-ascii?Q?gv/ISxOf8z4D9ruQEn2pcdfFTqsgSxXU5zNrBjNCpMKCKE9lLmUk2jDsAFt4?=
 =?us-ascii?Q?xM7YRTMEKIUGsWwmniPDkSEd954S2acHITtF9wIQGtS+slTeWqXSQtoSSQ+q?=
 =?us-ascii?Q?RXkiMsIo/d2W4fExo4E5fhomQZXhWGkuMJvVWxpgKYXxbhjVt518zKryfg9d?=
 =?us-ascii?Q?mwcJrvBFP9i+0fObOz29iZYA75nzXEmipGSjJ/D+0TdbNj3U23ndaUGRW+/H?=
 =?us-ascii?Q?stX1/w0baxpuVRQQ80dQUXqWnSeDkEHRmWm8U5XHxbepBx3NFVEEfynGrKod?=
 =?us-ascii?Q?Go/pPpmCv0wpmqnhpNn9AkP9jl1o17kuAXnUrr5Fb1AtZv9VitWqhSdjeLyN?=
 =?us-ascii?Q?Z77cglHUzMAcNzO9dFlEl/ecxukZNx1/rGj/Qldsig0zufoIsi8zaNvDnCQs?=
 =?us-ascii?Q?Dsx08SjHSssMb+8Lh9xNw1tWJlbAfaZxSHl4BsJCS/En3h9o1TkolfxaxwRb?=
Content-Language: en-us
x-ms-exchange-organization-originalclientipaddress: 213.184.59.150
x-ms-exchange-organization-originalserveripaddress: 10.167.242.27
dkim-signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=rhl.ee; q=dns/txt; s=zone; bh=0JU/g7j4QlMUP+BO8lWYsgRoiErNJxi/RB2QxY8cHeY=; h=from:subject:date:message-id:to:mime-version:content-type; b=PRlI0j1dcY9gYimqgp4Wh4ksgZg6dBYw9Igk+XgFGy0UcMy8uTsvePKGZCQ7kgkdbaIkE4wAJ 1mNocZs3+zgW/Gc6/RSKJ/V5ceLwWb1w7gRkcJIrQo7hMIudGc39cYgYBu9t6Clyb2BRMjBWUOZ lEt7KF7M1g21j9ssr2N8yVormC25Dx/dQAfQAMT2BV8SHnW8jeCPtFx8gE7qJnH/V34DAPrGH7H Ld+HtwZZ+vgSL5poG0Wue1r63CBg5M9ZnO3HQ0UTG5TDgw3SGGDnBLhbt5d2dOQFq07TEt/kthN MT7eih0YVls2BPJs6lL/8gRACtGWZbWOZ+8oIK+DE6CA==
received-spf: Pass (mail3.rit.ee: domain of  postmaster@MTA-244-115.TLL07.ZONEAS.EU designates  85.234.244.115 as permitted sender) identity=helo;  client-ip=85.234.244.115; receiver=mail3.rit.ee;  envelope-from="teet.torgo@rhl.ee";  x-sender="postmaster@MTA-244-115.TLL07.ZONEAS.EU";  x-conformance=spf_only; x-record-type="v=spf1";  x-record-text="v=spf1 ip4:217.146.64.0/20 ip4:185.31.240.0/22  ip4:85.222.232.0/22 ip4:85.234.242.0/23 ip4:85.234.244.0/22  ip6:2a02:29e8::/29 ip4:90.191.225.240/29  ip6:2001:7d0:d100:6::/64 ip4:90.191.225.208/28  ip4:87.119.168.48/29 ip4:217.68.24.144/29 ip4:45.151.4.0/23  -all"
X-Amp-Result: SKIPPED(no attachment in message)
X-Amp-File-Uploaded: False
X-MS-Exchange-ExternalInOutlookResult: NotEnabled
X-OlkEid: 00000000836E40BCE6F45249A1B797D09F9B03A3070034AD76187591974DBF6C4F76951C873A0100020000000000B781C84F2D6872479591B4ED6ECE3C5300000000B41100007DA6CED22DB41D46967E97BC612418CC
X-Ironport-Dmarc-Check-Result: validskip

This is a multipart message in MIME format.

------=_NextPart_000_0050_01DD728A.B1B3B220
Content-Type: text/plain;
	charset="utf-8"
Content-Transfer-Encoding: 8bit


Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.



Majandustegevuse seadustiku üldosa seaduse ja ravimiseaduse muutmise seaduse 
eelnõust



11.11.2026





Austatud proua minister



Kirjutan Teile Eesti Ravimihulgimüüjate Liidust (ERHL) seoses Majandus- ja 
Kommunikatsiooniministeeriumi poolt 29.10.2026 Justiits- ja 
Digiministeeriumile kooskõlastamiseks saadetud Majandustegevuse seadustiku 
üldosa seaduse ja ravimiseaduse muutmise seaduse (eksperimenteerimine 
majandustegevuses)“ eelnõuga (EIS toimik nr 25-1286).



Avastasin üllatusega, et pea aasta tagasi esimesel kooskõlastusringil käinud 
ja seejärel soikunud eelnõu on nüüd täiendatud ravimiseaduse muudatustega, 
millega antaks Ravimiametile õigus lubada ravimikäitlemise tegevusloaga 
ettevõtetel tegevusloa kõrvaltingimuse alusel „eksperimenteerimist“ ehk 
teisisõnu kõrvalekaldumist ravimiseaduse nõuetest.



Minu mureks on asjaolu, et teadaolevalt ei ole neid muudatusi sektoriga läbi 
räägitud – kindlasti mitte ERHLga kuigi muudatus puudutab meie 
tegevusvaldkonda otseselt. Kuna seletuskirja kohaselt olevat ravimite 
valdkonnas „vajadus ja õigustus“ eksperimenteerimiseks kõige selgemalt esile 
kerkinud, siis võiks eeldada, et sektori esindusorganisatsioonid kaasatakse 
ka seadusemuudatuse koostamise ja kooskõlastamise ametlikesse 
protsessidesse.



Täiendav murekoht tuleneb asjaolust, et nagu eelnõu selgitustes ka märgitud, 
siis ravimivaldkonda on peatselt nn regulatory sandbox lahendus EL õiguse 
kaudu ka lisandumas. Hetkel ei ole neid õigusakte EL-s veel lõplikult siiski 
vastu võetud. Eeldatavasti oleks EL eksperimenteerimiskorraldus kitsam kui 
praegu kavandatud siseriiklikus eelnõus. Seega tekib oht, et käesolevad 
muudatused tuleks peatselt uuesti avada.



Loodan Teie abile eelnõus nende murekohtade lahendamisele.





Lugupidamisega







Teet Torgo

Tegevjuht

ERHL

+372 517 8539




------=_NextPart_000_0050_01DD728A.B1B3B220
Content-Type: text/html;
	charset="utf-8"
Content-Transfer-Encoding: quoted-printable

<html xmlns:o=3D"urn:schemas-microsoft-com:office:office" =
xmlns:w=3D"urn:schemas-microsoft-com:office:word" =
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml" =
xmlns=3D"http://www.w3.org/TR/REC-html40"><head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; =
charset=3Dutf-8">
<meta name=3D"Generator" content=3D"Microsoft Word 15 (filtered =
medium)">
<style><!--
/* Font Definitions */
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Aptos;
	panose-1:2 11 0 4 2 2 2 2 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0cm;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
span.EmailStyle17
	{mso-style-type:personal-compose;
	font-family:"Aptos",sans-serif;
	color:windowtext;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-fareast-language:EN-US;}
@page WordSection1
	{size:612.0pt 792.0pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
	{page:WordSection1;}
--></style>
</head>
<body lang=3D"en-EE" link=3D"#467886" vlink=3D"#96607D" =
style=3D"word-wrap:break-word">
<table class=3D"MsoNormalTable" border=3D"0" cellspacing=3D"0" =
cellpadding=3D"0" align=3D"left" width=3D"100%" =
style=3D"width:100.0%;mso-cellspacing:0cm;mso-yfti-tbllook:1184; =
mso-table-lspace:2.25pt;mso-table-rspace:2.25pt;mso-table-anchor-vertical=
:paragraph;mso-table-anchor-horizontal:column;mso-table-left:left;mso-pad=
ding-alt:0cm 0cm 0cm 0cm">
<tbody>
<tr =
style=3D"mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes">
<td style=3D"background:#910A19;padding:5.25pt 1.5pt 5.25pt 1.5pt"></td>
<td width=3D"100%" =
style=3D"width:100.0%;background:#FDF2F4;padding:5.25pt 3.75pt 5.25pt =
11.25pt; word-wrap:break-word" cellpadding=3D"7px 5px 7px 15px" =
color=3D"#212121">
<div>
<p class=3D"MsoNormal" =
style=3D"mso-element:frame;mso-element-frame-hspace:2.25pt; =
mso-element-wrap:around;mso-element-anchor-vertical:paragraph;mso-element=
-anchor-horizontal: column;mso-height-rule:exactly">
<span style=3D"font-size:9.0pt;font-family: &quot;Segoe =
UI&quot;,sans-serif;mso-fareast-font-family:&quot;Times New =
Roman&quot;;color:#212121"><strong>T=C3=A4helepanu!
</strong>Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.<br>
Tundmatu saatja korral palume linke ja faile mitte =
avada.<o:p></o:p></span></p>
</div>
</td>
</tr>
</tbody>
</table>
<div>
<div class=3D"WordSection1">
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Majandustegevuse seadustiku =
=C3=BCldosa seaduse ja ravimiseaduse muutmise seaduse =
eeln=C3=B5ust<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span =
lang=3D"ET">11.11.2026<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Austatud proua =
minister<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Kirjutan Teile Eesti =
Ravimihulgim=C3=BC=C3=BCjate Liidust (ERHL) seoses Majandus- ja =
Kommunikatsiooniministeeriumi poolt 29.10.2026 Justiits- ja =
Digiministeeriumile koosk=C3=B5lastamiseks saadetud Majandustegevuse =
seadustiku =C3=BCldosa seaduse
 ja ravimiseaduse muutmise seaduse (eksperimenteerimine =
majandustegevuses)=E2=80=9C eeln=C3=B5uga (EIS toimik nr =
25-1286).<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Avastasin =C3=BCllatusega, et =
pea aasta tagasi esimesel koosk=C3=B5lastusringil k=C3=A4inud ja =
seej=C3=A4rel soikunud eeln=C3=B5u on n=C3=BC=C3=BCd t=C3=A4iendatud =
ravimiseaduse muudatustega, millega antaks Ravimiametile =C3=B5igus =
lubada ravimik=C3=A4itlemise tegevusloaga
 ettev=C3=B5tetel tegevusloa k=C3=B5rvaltingimuse alusel =
=E2=80=9Eeksperimenteerimist=E2=80=9C ehk teisis=C3=B5nu =
k=C3=B5rvalekaldumist ravimiseaduse n=C3=B5uetest.<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Minu mureks on asjaolu, et =
teadaolevalt ei ole neid muudatusi sektoriga l=C3=A4bi =
r=C3=A4=C3=A4gitud =E2=80=93 kindlasti mitte ERHLga kuigi muudatus =
puudutab meie tegevusvaldkonda otseselt. Kuna seletuskirja kohaselt =
olevat ravimite valdkonnas
 =E2=80=9Evajadus ja =C3=B5igustus=E2=80=9C eksperimenteerimiseks =
k=C3=B5ige selgemalt esile kerkinud, siis v=C3=B5iks eeldada, et sektori =
esindusorganisatsioonid kaasatakse ka seadusemuudatuse koostamise ja =
koosk=C3=B5lastamise ametlikesse protsessidesse.<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">T=C3=A4iendav murekoht tuleneb =
asjaolust, et nagu eeln=C3=B5u selgitustes ka m=C3=A4rgitud, siis =
ravimivaldkonda on peatselt nn
<i>regulatory sandbox</i> lahendus EL =C3=B5iguse kaudu ka lisandumas. =
Hetkel ei ole neid =C3=B5igusakte EL-s veel l=C3=B5plikult siiski vastu =
v=C3=B5etud. Eeldatavasti oleks EL eksperimenteerimiskorraldus kitsam =
kui praegu kavandatud siseriiklikus eeln=C3=B5us. Seega tekib oht, et
 k=C3=A4esolevad muudatused tuleks peatselt uuesti =
avada.<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Loodan Teie abile eeln=C3=B5us =
nende murekohtade lahendamisele.<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Lugupidamisega&nbsp; =
<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET"><o:p>&nbsp;</o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Teet =
Torgo<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">Tegevjuht<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">ERHL<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span lang=3D"ET">+372&nbsp;517 =
8539<o:p></o:p></span></p>
<p class=3D"MsoNormal"><span =
style=3D"font-size:11.0pt"><o:p>&nbsp;</o:p></span></p>
</div>
</div>
</body>
</html>

------=_NextPart_000_0050_01DD728A.B1B3B220--
